<DOC>
	<DOC>NCT00092482</DOC>
	<brief_summary>The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.</brief_summary>
	<brief_title>Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female with an intact uterus with lifetime history of 04 sexual partners Prior Human Papillomavirus Vaccine (HPV) vaccination; Prior abnormal paps; Prior history of genital warts</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>